<DOC>
	<DOCNO>NCT02873650</DOCNO>
	<brief_summary>To characterize pharmacokinetics safety dabrafenib follow single 100 mg oral dose subject moderate severe hepatic impairment .</brief_summary>
	<brief_title>Pharmacokinetics Dabrafenib Subjects With Hepatic Impairment</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>All female must nonchildbearing potential Other hepatic impairment , subject good health determine clinically significant finding medical history , physical exam , laboratory evaluation Subjects must BMI 18.0 kg/m2 36 kg/m2 , body weight least 50 kg 120 kg Additional criterion hepatic impairment subject : Subjects must stable ChildPugh status past 28 day prior dose Additional criterion healthy matched subject : Matched least 1 hepatic impairment subject age ( +/10 year ) , gender weight ( +/10 % ) Significant acute illness within two week prior dose History presence clinically significant ECG abnormality family history presence prolong QTinterval syndrome History current diagnosis cardiac disease indicate significant risk safety subject participate study uncontrolled significant cardiac disease Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug . History malignancy organ system , treat untreated , within 5 year , regardless recurrence metastasis . Healthy subject : History drug alcohol abuse within 6 month prior dose evidence abuse indicate laboratory value screen baseline . Additional exclusion hepatic impairment subject : History drug alcohol abuse within 1 month prior dose evidence abuse indicate laboratory value screen baseline . Subject receive liver transplant Encephalopathy Grade 3 worse within 28 day dose Subjects require tap every 3 month management ascites History surgical portosystemic shunt Subjects clinically significant abnormal finding , consistent clinical disease , upon physical examination , ECG laboratory evaluation . Other protocoldefined inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatic impairment</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Clinical pharmacology study</keyword>
	<keyword>DRB436</keyword>
	<keyword>dabrafenib</keyword>
	<keyword>normal hepatic function</keyword>
	<keyword>impaired hepatic function</keyword>
</DOC>